BackNewAmsterdam Pharma Company NV - Warrants (15/11/2027) Overview

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Receivables

NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s receivables is $24M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$24.00M
21.50% YoYΔ $4.25M vs prior year quarter

Peer trimmed avg / median

Loading

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Receivables History

Loading

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) vs. peers: Receivables Comparison

Loading

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) (NAMSW) FAQ

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) (NAMSW) currently reports a receivables of $24M as of June 2026. That compares with $20M in the prior-year period — up 21.5% year over year. Use the charts on this page to explore NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s receivables history and peer comparisons.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s receivables increased from $20M to $24M — a 21.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) reported $24M in receivables as of June 2026. That compares with $20M in the prior-year period — up 21.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $24M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV - Warrants (15/11/2027), and consider following NAMSW for alerts when major investors trade the stock.